RASAL1 and cancer: Overexpression of PTP1B can weaken the efficacy of sorafenib and regorafenib in cancer cells, and this PTP1B-dependent PITX-RASAL1-RAS axis change also directly affects the efficacy of sorafenib in treating liver cancer (84, 85).